全部分类
  • L-779,450
L-779,450的可视化放大

L-779,450

A B-Raf inhibitor

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

L-779,450的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 10mg
    ¥1150.00
    920.00
    - +
  • 50mg
    ¥4850.00
    3880.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajci16090
  • CAS: 303727-31-3
  • 别名: 4-(4-氯-3-羟基苯基)-2-苯基-5-(吡啶-4-基)-1H-咪唑
  • 分子式: C20H14ClN3O
  • 分子量: 347.8
  • 纯度: >98%
  • 溶解度: DMF: 30 mg/mL,DMF:PBS (pH 7.2); (1:7): 0.12 mg/mL,DMSO: 30 mg/mL,Ethanol: 2 mg/mL
  • 储存: Store at -20°C
  • 库存: 现货

Background

L-779450 is a potent and selective B-Raf kinase inhibitor with a Kd of 2.4 nM.


L-779450 (L-779,450) shows a high degree of specificity towards Raf. The only other tested kinase inhibited is p38MAPK, which has a kinase domain structurally related to Raf. L-779450 inhibits anchorage-independent growth of human tumor lines at doses ranging from 0.3 to 2?μM[2]. The effects of L-779450 (L-779,450) on TRAIL sensitivity are investigated here in melanoma cell lines with high TRAIL sensitivity (A-375 and SK-Mel-147), moderate sensitivity (Mel-HO, SK-Mel-13, and SK-Mel-28), and permanent resistance (MeWo, Mel-2a, and SK-Mel-103), as well as in TRAIL-selected cell lines with acquired resistance (A-375-TS and Mel-HO-TS). Despite only moderate direct effects of L-779450 on apoptosis, it strongly enhances TRAIL-induced apoptosis in sensitive melanoma cells and overrules TRAIL resistance in Mel-2a, SK-Mel-103, A-375-TS, and Mel-HO-TS. At 24?hours, 16-35% apoptosis induction is obtained[3].


参考文献:
[1]. Takle AK, et al. The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4373-6.
[2]. Shelton JG, et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia. 2003 Sep;17(9):1765-82.
[3]. Berger A, et al. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol. 2014 Feb;134(2):430-440.

Protocol

Cell experiment:

For induction of apoptosis, TRAIL (20?ng/mL), the pan-RAF inhibitor L-779450 (0.1-50?μM), the MEK inhibitor U0126 (20?μM), and the selective BRAF(V600E) inhibitor Vemurafenib/PLX4032 are used. For continuous monitoring cell growth, the xCELLigence system is applied. Relative cell indices correspond to attached cell numbers. Cell cycle analyses are performed for quantification of apoptosis and cell cycle arrest. Cells harvested by trypsinization are stained for 1?hour with propidium iodide (200?mg/mL), and sub-G1 fractions, corresponding to cells with fragmented DNA, are quantified by flow cytometry[3].

参考文献:

[1]. Takle AK, et al. The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4373-6.
[2]. Shelton JG, et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia. 2003 Sep;17(9):1765-82.
[3]. Berger A, et al. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol. 2014 Feb;134(2):430-440.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算